- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Advocacy
- Careers
- About
- For Pain Patients and Professionals
Although mu-opioid receptor agonists have been the mainstay of analgesic regimens for moderate to severe pain, they are associated with serious side effects, risks, and limitations. We evaluate the most serious risks associated with conventional opioids and compare these with the pharmacology of CYT-1010, a prototypical endomorphin and mu-opioid receptor agonist.